Podcasts

Author Interview: Dr Saqr Alsakarneh, May 2025

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Saqr Alsakarneh, Internal Medicine Resident at University of Missouri–Kansas City in the US, as they discuss ‘Risk of De Novo Inflammatory Bowel Disease in Patients with Psoriasis and Psoriatic Arthritis Treated with IL-17A Inhibitors: A Population-Based Study’.

Discussing RA: MACE, VTE, and malignancy in filgotinib RA and UC patients, and MACE related to JAKis

Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA.

In this episode, he discusses two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.

Discussing axSpA: JAKi cycling and long-term safety of bimekizumab in patients with axSpA or PsA

Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.

In this episode, our faculty discusses two papers: the first assesses switching to secukinumab or cycling with other TNF inhibitors, and the second investigates long-term safety of bimekizumab in adult patients with axSpA or PsA.

Webinar Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA

Join Dr Sofia Ramiro and Professors Atul Deodhar and Laura Coates as they discuss the recent webinar hosted on the IMID Forum: “IL-17 Inhibition: Controlling inflammation and disease progression in SpA”. Watch them discuss key highlights from the webinar including the role of IL-17A and IL-17A/F dual inhibitors in the management of axSpA, and role of IL-17A and IL-17A/F dual inhibitors in the management of PsA.

Discussing PsA: JAKi Comparative safety and Burden and determinants of multi‑b/tsDMARD failure in PsA

Join Professors Laura Coates and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis. They also give insights into the burden and determinants of multi‑b/tsDMARD failure in psoriatic arthritis.

Discussing RA: Pain reduction & choosing second-line DMARDs after unresponsive first-line DMARDs

Join Professors Iain McInnes and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA.

In this episode, they discuss two papers: effectiveness of JAKi compared with bDMARDs on pain reduction and effective second‑line b/tsDMARD for patients with rheumatoid arthritis unresponsive to first‑line b/tsDMARDs.